# **GORE® TAG®**

**Conformable Thoracic Stent Graft** with ACTIVE CONTROL System

## DEPLOYMENT SEQUENCE



### Device positioning to target

- Position device on outer curve.
- Release stored energy in the device catheter: Advance stent graft past target location and pull back to desired position.



#### Verify proximal alignment marker position

**OPTIONAL:** Steps to optimize positioning

If optional angulation control will be used, ensure the proximal alignment marker is positioned toward the greater curve relative to the guidewire.



#### Primary deployment to intermediate diameter

Rotate and pull gray Primary Deployment Handle. Device will deploy to its intermediate diameter (~50% of device nominal diameter).



#### Angulation control at intermediate diameter

- Angulation Control Dial clockwise until proximal angulation is optimized.
- Proximal angulation cannot be reversed or undone.
- Therefore, rotate the Angulation Control Dial slowly and deliberately throughout this step, using only the smallest angulation necessary to achieve desired graft alignment.

#### Angulation control at full diameter

- At the physician's discretion, rotate Angulation Control Dial clockwise until proximal angulation is optimized.
- Proximal angulation cannot be reversed or undone.
- Therefore, rotate the Angulation Control Dial slowly and deliberately throughout this step, using only the smallest angulation necessary to achieve desired graft alignment.



#### Secondary deployment to full diameter

- Rotate and pull gray Secondary Deployment Handle. Device will deploy to its full diameter.
- At this stage, the stent graft is still attached to the catheter (via lockwire).



3a



#### Lockwire removal

- Rotate and pull red Lockwire Handle. Lockwire removal releases the stent graft from the catheter.
- Pull with a steady motion.



#### Angulation assembly removal

- Pull back red slider, rotate and pull gray Angulation Assembly Handle.
- Pull with a steady and



At physician discretion, rotate the

continuous motion. Withdraw catheter under fluoroscopy to ensure safe removal from stent graft.



### Consult Instructions for Use eifu.goremedical.com

INDICATIONS FOR USE IN THE U.S.: The GORE® TAG® Thoracic Endoprosthesis is intended for endovascular repair of all lesions of the descending thoracic aorta, including: Isolated lesions in patients who have appropriate anatomy, including: adequate iliac/femoral access, aortic inner diameter in the range of 16–42 mm, ≥ 20 mm non-aneurysmal aorta proximal and distal to the lesion; Type B dissections in patients who have appropriate anatomy, including: adequate inac/remota access, all times of interfage of 10-42 mm (2 20 mm horizonta) since a proximal and the bioline proximal access, all times of interfage of 10-42 mm (2 20 mm horizonta) since a proximal and the bioline proximal extents of the landing zone must not be dissected, diameter at proximal extent of proximal interfage of 10-42 mm. Contracind or proximal extents of the device materials; patients who have a condition that threatens to infect the graft. Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions, and adverse events.  $R_{X \text{ only}}$  **INDICATIONS FOR USE UNDER CE MARK:** The GORE® TAG® Conformable Thoracic Stent Graft is indicated for endovascular repair of all lesions of the descending thoracic aorta, including isolated lesions, such as aneurysm and traumatic transection, and Type B dissections. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials of the descending thoracic aorta, including isolated lesions, such as aneurysm and traumatic transection, and Type B dissections. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials of the descending thoracic aorta, including isolated lesions, such as aneurysm and traumatic transection, and Type B dissections. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials for the avector and real materials. to the device materials; patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available.  $R_{X \text{ Only}}$ 

Products listed may not be available in all markets.

GORE, Together, improving life, ACTIVE CONTROL, TAG and designs are trademarks of W. L. Gore & Associates. © 2017, 2019, 2022 W. L. Gore & Associates, Inc. 22642235-EN JULY 2022

W. L. Gore & Associates, Inc. Asia Pacific +65 67332882 Australia/New Zealand 1800 680 424 Europe 00800 6334 4673 United States Flagstaff, AZ 86004 800 437 8181 928 779 2771 goremedical.com



Together, improving life